imatinib mesylate has been researched along with Squamous Cell Carcinoma of Head and Neck in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cordes, N; Dickreuter, E; Koppenhagen, P | 1 |
| O'Bryan, KW; Ratner, D | 1 |
1 review(s) available for imatinib mesylate and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer.
Topics: Anilides; Antineoplastic Agents; Benzamides; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatofibrosarcoma; ErbB Receptors; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms, Squamous Cell; Piperazines; Pyridines; Pyrimidines; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck | 2011 |
1 other study(ies) available for imatinib mesylate and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
Topics: Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Combined Modality Therapy; DNA Breaks, Double-Stranded; Head and Neck Neoplasms; HeLa Cells; Humans; Imatinib Mesylate; Immunoglobulin G; Integrin beta1; MCF-7 Cells; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck | 2017 |